I-Mab, a U.S.-based biotech firm, reported promising financial and clinical advancements in its third-quarter 2024 results. The company is set to initiate a Phase 2 study for uliledlimab in lung ...

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced its intent to change the ...

Zoomcar Holdings, Inc.  ('Zoomcar,' or 'we,' or 'our'), the leading marketplace for car sharing in India, today announced results for its second quarter ended September 30, 2024. Hiroshi Nishijima, ...

Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare disease targets.

Vera Therapeutics appointed Amgen and Seagen alum Matt Skelton as EVP of commercial. Frank Lane was appointed SVP and head of ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

From the company's own site, we can see this pharma brand has a diversified portfolio of therapies across multiple clinical ...

An iconic sign is returning to one of St. Louis' thoroughfares.  The neon Anheuser-Busch sign with the beer company's legendary logo of a giant "A" and an eagle flying through it is glowing and moving ...

The importance of early-stage CMC de-risking Dan Jacobs discussed his experience at Pioneering Medicines, where the company ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...